Cizzle Biotechnology Holdings Plc, together with its subsidiaries, engages in the development of an immunoassay test for the CIZ1B biomarker for the early detection of lung cancer in the United Kingdom. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.
Stock data | 2024 | Change |
---|---|---|
Price | $0.027720210673601125 | N/A |
Market Cap | $10.09M | N/A |
Shares Outstanding | 363.84M | N/A |
Employees | 4.00 | N/A |